Elite Pharma Inc (ELTP) 0.2118 $ELTP Elite

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Elite Pharma Inc (ELTP) 0.2118 $ELTP

Elite Pharmaceuticals awarded new US patent for abuse deterrent technology
M2 - Wed Jun 17, 4:25AM CDT
Pharmaceutical company Elite Pharmaceutical (OTCBB:ELTP) reported on Tuesday the receipt of the US Patent entitled "Abuse-Resistant Oral Dosage Forms" for its opioid abuse deterrent technology.

Elite Pharmaceutical's (ELTP) CEO Nasrat Hakim on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Jun 16, 7:50PM CDT


Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Jun 16, 9:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled "Abuse-Resistant Oral Dosage Forms". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals posts 9% higher record consolidated revenues for fiscal 2015
M2 - Tue Jun 16, 5:58AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Monday it recorded consolidated revenues of USD5.015m for the fiscal year ended 31 March 2015 (fiscal 2015).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Mon Jun 15, 3:58PM CDT
Elite Pharmaceuticals Reports Nine Percent Revenue Growth

CORRECTION -- Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 5:24PM CDT
In the press release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP) with the same headline, please note that the conference call date should be Tuesday, June 16, 2015 and not Tuesday, July 16, 2015 as previously stated in the conference call details. All other information remains the same.

Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 3:00PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its year end financial results will be released on Monday, June 15, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, June 16 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals and Epic Pharma to market abuse-deterrent technology ELI-200
M2 - Wed Jun 10, 4:20AM CDT
Pharmaceutical company Elite Pharmaceuticals (NasdaqGS:ELTP) reported on Tuesday the launch of a sales and distribution licensing agreement for its abuse-deterrent opioid utilising its proprietary pharmacological abuse-deterrent technology, ELI-200, with Epic Pharma.

Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
GlobeNewswire - Tue Jun 09, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the "License", an abuse-deterrent opioid utilizing Elite's proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments totaling $15 million and a royalty based on net product sales. The term of the License is five years and the License is renewable upon mutual agreement at the end of the initial term.

Elite Pharmaceuticals unveils generic Hydroxyzine Tablets
M2 - Wed Apr 22, 6:12AM CDT
Pharmaceutical company Elite Pharmaceuticals (OtherOTC:ELTP) revealed on Tuesday the availability of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions.

Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
GlobeNewswire - Tue Apr 21, 9:02AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) today announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma LLC, a private pharmaceutical company located in Laurelton, NY. Hydroxyzine is indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions. Annual U.S. sales for immediate release Hydroxyzine HCI 10 mg and 25 mg and 50 mg tablets are approximately $40 million for the twelve months ending June 30, 2014 according to IMS Health Data. Epic will manufacture, package and distribute the product under the Manufacturing and License Agreement previously signed between Epic and Elite.

FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST

MNK: 122.44 (+2.18), LCI: 59.93 (+2.37), ACT: 298.98 (-2.94), EGLT: 12.42 (+0.36), ZGNX: 15.17 (+1.95), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), TEVA: 61.38 (-0.75), ALKS: 64.22 (+1.88), ACUR: 0.92 (+0.03)

Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST


Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST

MNK: 122.44 (+2.18), LCI: 59.93 (+2.37), EGLT: 12.42 (+0.36), ACT: 298.98 (-2.94), ZGNX: 15.17 (+1.95), PFE: 34.36 (+0.50), ABBV: 69.23 (+1.26), TEVA: 61.38 (-0.75), ALKS: 64.22 (+1.88), ACUR: 0.92 (+0.03)

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter

Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete.

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
GlobeNewswire - Thu Feb 12, 1:49PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, February 18, 2015 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST

PPHM: 1.29 (+0.06)

Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 298.98 (-2.94), ZGNX: 15.17 (+1.95), PFE: 34.36 (+0.50)

Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 12.42 (+0.36), ACT: 298.98 (-2.94), PFE: 34.36 (+0.50), ACUR: 0.92 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading